

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/809,497		03/26/2004	Takashi Yamamoto	011350-334	7869
21839	839 7590 03/23/2006			EXAMINER	
		ERSOLL PC	BOUCHELL	BOUCHELLE, LAURA A	
(INCLUDIT		IS, DOANE, SWECK	ART UNIT	PAPER NUMBER	
ALEXANDRIA, VA 22313-1404				3763	

DATE MAILED: 03/23/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
		10/809,497	YAMAMOTO ET AL.					
Office Action Summary		Examiner	Art Unit					
		Laura A. Bouchelle	3763					
	The MAILING DATE of this communication app							
Period fo	r Reply							
WHIC - Exter after - If NO - Failu Any I	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE asions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).					
Status								
1)⊠	Responsive to communication(s) filed on $\underline{22 De}$	ecember 2005.						
′=	This action is FINAL . 2b)⊠ This action is non-final.							
3)∐	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠	Claim(s) <u>1-15</u> is/are pending in the application.		•					
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) 13 and 14 is/are allowed.							
·	☑ Claim(s) <u>1-12 and 15</u> is/are rejected.							
	Claim(s) is/are objected to.	-1-6						
8)	Claim(s) are subject to restriction and/or	election requirement.						
Applicati	on Papers							
9)[The specification is objected to by the Examine	г.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)	Replacement drawing sheet(s) including the correcti The oath or declaration is objected to by the Ex							
Priority ι	ınder 35 U.S.C. § 119							
a)l	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority documents application from the International Bureau	s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No· ed in this National Stage					
* S	See the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached detailed Office action for a list of the attached	of the certified copies not receive	d.					
1) Notic	e of References Cited (PTO-892)	4) Interview Summary						
3) 🔯 Infor	te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) or No(s)/Mail Date 8/17/2004.	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate ratent Application (PTO-152)					

Response to Amendment

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 1, 2, 4, 6, 8, 12, 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chee in view of Iancea et al (US 6190360).
- 3. Chee discloses a catheter for percutaneous insertion comprising a sheath 130 with a lumen 132 extending therein, an injection needle 134 with a beveled edge located at the distal end of an insertion member disposed slidably in the lumen of the sheath with a distal portion capable of protruding from the distal end portion of the sheath, three sets of paired electrodes 136, 138, 140 disposed in the distal portion of the catheter for measuring impedance (Page 8, paragraph 118). See Figs. 12A and 12B. The target tissue of the invention disclosed by Chee is the heart (see abstract).
- 4. Regarding claim 15, Chee discloses a method for treating the heart including inserting the catheter into the living body and advancing it to the neighborhood of the target tissue (Page 21, Claim 33). Chee further discloses the step of puncturing the target tissue based on measurements

Application/Control Number: 10/809,497 Page 3

Art Unit: 3763

from the electrodes (Page 22, Claims 50 and 52). Chee further discloses the step of injecting

therapeutic composition into the target tissue (Page 22, Claim 39).

5. Claims 1 and 15 differ from Chee in calling for at least one of the electrodes to be

disposed at the distal end of the member. Claim 2 differs from Chee in calling for the electrodes

to be disposed on the distal end of the insertion member. Claim 4, calls for the electrodes to be

located on the insertion member. Claim 6 differs in calling for electrodes to be located on both

the insertion member and the sheath. Claim 8, depending from claim 6, calls for the pairs of

electrodes to be individually parted longitudinally as is depicted by Chee. Iancea discloses a

percutaneous insertion catheter comprising a sheath 192 and an inner member 194, wherein

electrodes 196 are disposed on the distal end of the insertion member (Col. 8, lines 32-35).

Iancea further discloses that this configuration allows the electrodes to be positioned in the

treatment location (Col. 8, lines 50-58). Therefore, it would have been obvious to one of

ordinary skill in the art at the time of invention to place the electrodes of Chee on the insertion

member as taught by Iancea so that the electrodes can be positioned at the treatment location.

6. Claims 3, 5, 7, 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chee in

view of Iancea as applied to claims 2, 4, 6, 8 above, and further in view of Tollner et al (US

2001/0031942). Claim 3 differs from the teaching of Chee in view of Iancea in calling for the

electrodes to be located not less that 1 mm from the leading edge of the insertion needle. Tollner

discloses a percutaneous insertion catheter comprising sensing electrodes 6 located

approximately 3 mm from the tip 4 of the catheter (Page 2, paragraph 30). This configuration

Art Unit: 3763

increase perceptivity lengthwise.

eliminates the disadvantage of electrode configurations that are hard to position by offering increased perceptivity lengthwise (Page 1, paragraph 14). Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to place the electrodes of Chee in view of Iancea more than 1mm from the leading edge of the insertion member as taught by Tollner to

Page 4

7. Claim 10 is rejected under 35 U.S.C. 103(a) as being unpatentable over Chee in view of Iancea as applied to claim 1 above, and further in view of Lederman (US 2003/0032936). Claim 10 differs from Chee in calling for the distal end portion of the sheath to have a through hole communicating with the lumen. Lederman discloses a catheter 10 with a side through hole 16 in fluid communication with the lumen through which therapeutic or diagnostic agents may be delivered (Page 1, paragraph 10). Therefore, it would have been obvious to one of ordinary skill

in the art at the time of invention to modify the sheath disclosed by Chee to include a side port as

taught by Lederman to deliver therapeutic or diagnostic agents.

8. Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Chee in view of Iancea in view of Lederman as applied to claim 10 above. Claim 11 differs from the teachings of Chee in view Iancea in further view of Lederman in calling for the through hole to be separated by not less than 1 mm from the end face of the distal end portion. At the time the invention was made, it would have been an obvious matter of design choice to place the through hole not less than 1 mm from the end face. Applicant has not disclosed that this distance serves any advantage or particular purpose of solves a stated problem. Furthermore, one of ordinary skill

would expect the device of Chee in view of Lederman to perform equally well with the through

hole placed in any location. Therefore, it would have been prima facie obvious to modify the

device of Chee in view of Lederman as specified in claim 11 because such a modification would

have been considered a mere design consideration which fails to patentably distinguish over the

prior art of Chee in view of Lederman.

Allowable Subject Matter

- 9. Claims 13 and 14 are allowable over the prior art.
- 10. The following is a statement of reasons for the indication of allowable subject matter: A puncture detecting device connected to conductors and electrodes for sensing puncture based on impedance in combination with the other claimed features was not found in the prior art.

Response to Arguments

- 11. Applicant's arguments filed 12/22/2005 have been fully considered but they are not persuasive.
- 12. Applicant states that it would not have been obvious to combine the Chee and Iancea references to teach the location of the electrodes on the probe. In response to this argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the

claimed invention where there is some teaching, suggestion, or motivation to do so found either

Page 6

in the references themselves or in the knowledge generally available to one of ordinary skill in

the art. See In re Fine, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and In re Jones, 958

F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, Iancea teaches that the placement of

the electrodes allows the clinician to advance the catheter to the treatment site as stated above.

13. In response to applicant's argument that Iancea provides electrodes for a different purpose

than the current application, a recitation of the intended use of the claimed invention must result

in a structural difference between the claimed invention and the prior art in order to patentably

distinguish the claimed invention from the prior art. If the prior art structure is capable of

performing the intended use, then it meets the claim.

14. Applicant's arguments, see page 12, filed 12/22/2005, with respect to the Hill reference

have been fully considered and are persuasive. The rejection of claims 13 and 14 has been

withdrawn.

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Laura A. Bouchelle whose telephone number is 571-272-2125.

The examiner can normally be reached on Monday-Friday 8-4.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Nicholas Lucchesi can be reached on 517-272-4977. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/809,497 Page 7

Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Laura A Bouchelle Examiner Art Unit 3763

LAB